AJP - Regu Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 276: R929-R934, 1999;
0363-6119/99 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vijayan, A.
Right arrow Articles by Miller, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vijayan, A.
Right arrow Articles by Miller, S. B.
Vol. 276, Issue 4, R929-R934, April 1999

Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure

Anitha Vijayan, Samuel C. Franklin, Terry Behrend, Marc R. Hammerman, and Steven B. Miller

George M. O'Brien Kidney and Urologic Diseases Center, Renal Division, Department of Internal Medicine and Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri 63110

There is no pharmacological treatment to increase the glomerular filtration rate in end-stage renal disease (ESRD). The administration of 100 µg/kg of insulin-like growth factor (IGF) I twice a day to patients with ESRD increases inulin clearance. However, its effect is short-lived and IGF-I has major side effects when given this way. To assess whether the use of a lower intermittent dose of IGF-I would effect sustained improved function with tolerable side effects we performed 1) a prospective open-labeled 24-day trial in which we enrolled five patients and 2) a 31-day randomized, double-blinded, placebo-controlled trial in which we enrolled 10 patients. Patients with ESRD [creatinine clearance of <15 ml · min-1 · (1.73 m2)-1] and scheduled to initiate renal replacement therapy received subcutaneous IGF-I, 50 µg · kg-1 · day-1, or vehicle. Treatment with IGF I resulted in significantly increased glomerular filtration rates (inulin clearances) during the 3rd and 4th wk of therapy in both prospective and double-blinded studies. Vehicle had no effect. No patient required discontinuation of drug secondary to side effects. We conclude that IGF-I effects sustained improvement of renal function (clearances comparable to those generally achieved by dialysis) in patients with ESRD and is well tolerated.

dialysis; glomerular filtration rate; growth factor; middle molecules


This article has been cited by other articles:


Home page
 Diabetes CareHome page
C. M. Clark Jr., M. H. Chin, S. N. Davis, E. Fisher, R. G. Hiss, D. G. Marrero, E. A. Walker, and J. Wylie-Rosett
Incorporating the Results of Diabetes Research Into Clinical Practice: Celebrating 25 years of Diabetes Research and Training Center translation research
Diabetes Care, December 1, 2001; 24(12): 2134 - 2142.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
V. ROELFSEMA and R. G. CLARK
The Growth Hormone and Insulin-Like Growth Factor Axis: Its Manipulation for the Benefit of Growth Disorders in Renal Failure
J. Am. Soc. Nephrol., June 1, 2001; 12(6): 1297 - 1306.
[Abstract] [Full Text]

Home page
 Nephrol Dial TransplantHome page
M. R. Hammerman
`The growth hormone–insulin-like growth factor axis in kidney re-revisited
Nephrol. Dial. Transplant., August 1, 1999; 14(8): 1853 - 1860.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online